{
    "Rank": 519,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00847171",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "J0885"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA006973",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA006973"
                        },
                        {
                            "SecondaryId": "NA_00021048",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "JHM IRB"
                        },
                        {
                            "SecondaryId": "CDR0000634155",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "other"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer",
                "OfficialTitle": "A Safety and Bioactivity Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of Patients With High Risk/ Metastatic HER-2/Neu- Overexpressing Breast Cancer With No Evidence of Disease"
            },
            "StatusModule": {
                "StatusVerifiedDate": "September 2018",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "December 2008"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 2013",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "June 2013",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "February 18, 2009",
                "StudyFirstSubmitQCDate": "February 18, 2009",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "February 19, 2009",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "August 28, 2018",
                "ResultsFirstSubmitQCDate": "September 25, 2018",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "September 26, 2018",
                    "ResultsFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "September 25, 2018",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "September 26, 2018",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {},
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Giving trastuzumab together with cyclophosphamide and vaccine therapy may kill more tumor cells.\n\nPURPOSE: This phase II trial is studying the side effects of giving trastuzumab together with cyclophosphamide and vaccine therapy in treating patients with high-risk or metastatic breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nTo evaluate the safety of allogeneic sargramostim (GM-CSF)-secreting breast cancer vaccine in combination with trastuzumab (Herceptin\u00ae) and cyclophosphamide in patients with high-risk or metastatic HER2/neu-overexpressing breast cancer.\nTo measure the HER2/neu-specific CD4+ T-cell response by delayed-type hypersensitivity.\nTo measure the magnitude of HER2/neu-specific CD8+ T-cell responses by ELISPOT.\n\nSecondary\n\nTo assess the impact of trastuzumab on immune priming in vivo by IHC.\nTo measure the impact of cyclophosphamide pretreatment on CD4+CD25+ regulatory T cells by flow cytometry.\nTo determine the time to disease progression.\n\nTertiary\n\nTo develop the tandem tetramer/CD107a cytotoxicity assay for HER2/neu-specific CD8+ T cells.\nTo measure novel T-cell responses induced by trastuzumab and cyclophosphamide-modulated vaccination.\n\nOUTLINE: Patients receive trastuzumab (Herceptin\u00ae) IV over 30-90 minutes once weekly beginning on day -1 of the first course of vaccination and continuing until the completion of the last course of vaccination. Patients also receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic sargramostim (GM-CSF)-secreting breast cancer vaccine intradermally on day 0. Treatment with cyclophosphamide and the vaccine repeats every 27-42 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth course of cyclophosphamide and vaccine approximately 6-8 months after the first course.\n\nPatients undergo delayed-type hypersensitivity testing and blood sample collection at baseline and periodically during study for immunologic laboratory studies. Blood samples are analyzed for serum GM-CSF levels by pharmacokinetic studies and for immune monitoring by ELISPOT and flow cytometry. Skin punch biopsies are also performed periodically and analyzed by IHC.\n\nAfter completion of study treatment, patients are followed periodically."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "male breast cancer",
                        "stage II breast cancer",
                        "stage IIIA breast cancer",
                        "stage IIIB breast cancer",
                        "stage IIIC breast cancer",
                        "stage IV breast cancer",
                        "HER2-positive breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "20",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: allogeneic GM-CSF-secreting breast cancer vaccine",
                                    "Biological: trastuzumab",
                                    "Drug: cyclophosphamide",
                                    "Other: flow cytometry",
                                    "Other: immunoenzyme technique",
                                    "Other: immunohistochemistry staining method",
                                    "Other: laboratory biomarker analysis",
                                    "Other: pharmacological study",
                                    "Procedure: biopsy"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "allogeneic GM-CSF-secreting breast cancer vaccine",
                            "InterventionDescription": "Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:\n\n12 intradermal injections of a divided total dose of 5 x108 cells.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "trastuzumab",
                            "InterventionDescription": "Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.\n\nPatient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Herceptin"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "cyclophosphamide",
                            "InterventionDescription": "Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Cytoxan"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "flow cytometry",
                            "InterventionDescription": "Samples will be analyzed by flow cytometry using Cell Quest software",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "immunoenzyme technique",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "immunohistochemistry staining method",
                            "InterventionDescription": "Measuring Immune Priming In Vivo By Vaccine Site Biopsies",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "laboratory biomarker analysis",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "pharmacological study",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "biopsy",
                            "InterventionDescription": "skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Safety as Assessed by Number of Participants Experiencing Toxicity",
                            "PrimaryOutcomeDescription": "Safety as assessed by number of participants who experienced drug-related local and systemic toxicity, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0) in response to CY-modulated immunization with a novel breast cancer vaccine in the setting of weekly Trastuzumab therapy.",
                            "PrimaryOutcomeTimeFrame": "4 years"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Number of Participants With Immunologic Response as Determined by Delayed-type Hypersensitivity (DTH) Response to HER2/Neu-derived Peptides",
                            "PrimaryOutcomeTimeFrame": "4 years"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Clinical Benefit as Assessed by Number of Participants With Progression-free Survival",
                            "SecondaryOutcomeDescription": "Number of participants without evidence of disease progression.",
                            "SecondaryOutcomeTimeFrame": "4 years"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed adenocarcinoma of the breast, meeting one of the following criteria:\n\nMetastatic disease\n\nHigh-risk disease, defined as early-stage disease with pathologic involvement of locoregional lymph nodes\n\nPatients who are/will be receiving standard adjuvant trastuzumab [Herceptin\u00ae] for high-risk disease will participate in this study during the single-agent trastuzumab portion of their therapy\nNo clinical or radiographical evidence of active disease\nNot eligible for therapy of known curative potential for metastatic breast cancer\nHER2/neu-overexpressing disease, defined as HER2/neu positive by IHC 3+ staining or by FISH+ amplification\nStable CNS disease allowed provided it has been adequately treated and is not under active treatment\nHormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nMenopausal status not specified\nECOG performance status 0-1\nANC > 1,000/mm^3\nPlatelet count > 100,000/mm^3\nSerum creatinine < 2.0 mg/dL\nSerum bilirubin \u2264 2.0 mg/dL (unless elevation is due to known Gilbert's syndrome)\nAST/ALT \u2264 2 times upper limit of normal (ULN)\nAlkaline phosphatase \u2264 5 times ULN\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nCardiac ejection fraction normal by MUGA OR \u2265 45% by ECHO\nNo other malignancies within the past 5 years, except for carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, or superficial bladder cancer\n\nNo prior or currently active autoimmune disease* requiring management with systemic immunosuppression, including any of the following:\n\nInflammatory bowel disease\nSystemic vasculitis\nScleroderma\nPsoriasis\nMultiple sclerosis\nHemolytic anemia or immune-mediated thrombocytopenia\nRheumatoid arthritis\nSystemic lupus erythematosus\nSj\u00f6gren syndrome\nSarcoidosis\nOther rheumatologic disease\nNo symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest\nHIV-negative\nNo evidence of active acute or chronic infection\nNo uncontrolled medical problems\nNo active major medical or psychosocial problems that could be complicated by study participation\nNo corn allergy\nNo known severe hypersensitivity to trastuzumab (except for mild to moderate infusion reactions that are easily managed and do not recur) NOTE: *Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed\n\nPRIOR CONCURRENT THERAPY:\n\nAny number of prior chemotherapy regimens for metastatic breast cancer allowed\nPrior or concurrent trastuzumab in the adjuvant or metastatic setting allowed\n\nMore than 28 days since prior and no concurrent systemic oral steroids\n\nTopical, ocular, or nasal steroids allowed\nMore than 28 days since prior and no concurrent chemotherapy, radiotherapy, or biologic therapy (except trastuzumab)\nMore than 28 days since prior and no concurrent participation in another investigational clinical trial involving a new drug\nConcurrent endocrine therapy or bisphosphonates allowed",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Leisha A. Emens, MD, PhD",
                            "OverallOfficialAffiliation": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                            "LocationCity": "Baltimore",
                            "LocationState": "Maryland",
                            "LocationZip": "21231-2410",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
                            "FlowGroupDescription": "Patients receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "20"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "20"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
                            "BaselineGroupDescription": "Patients receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "20"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "47",
                                                                "BaselineMeasurementLowerLimit": "34",
                                                                "BaselineMeasurementUpperLimit": "66"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "20"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Safety as Assessed by Number of Participants Experiencing Toxicity",
                            "OutcomeMeasureDescription": "Safety as assessed by number of participants who experienced drug-related local and systemic toxicity, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0) in response to CY-modulated immunization with a novel breast cancer vaccine in the setting of weekly Trastuzumab therapy.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "4 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
                                        "OutcomeGroupDescription": "All patients receive weekly Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "20"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Patients with drug-related toxicity",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Patients with grade 3+ drug-related toxicity",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Patients with serious drug-related toxicity",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Number of Participants With Immunologic Response as Determined by Delayed-type Hypersensitivity (DTH) Response to HER2/Neu-derived Peptides",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "4 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
                                        "OutcomeGroupDescription": "Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "20"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "DTH-positive at baseline",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "12"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Increased DTH from baseline",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Converted from DTH-negative to DTH-positive",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Clinical Benefit as Assessed by Number of Participants With Progression-free Survival",
                            "OutcomeMeasureDescription": "Number of participants without evidence of disease progression.",
                            "OutcomeMeasurePopulationDescription": "Only 13/20 participants had early stage disease, and 7/20 participants had a history of metastatic disease at the start of the study. All participants were assigned to the same treatment group.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "4 years",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
                                        "OutcomeGroupDescription": "Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "20"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Patients with early stage disease",
                                        "OutcomeClassDenomList": {
                                            "OutcomeClassDenom": [
                                                {
                                                    "OutcomeClassDenomUnits": "Participants",
                                                    "OutcomeClassDenomCountList": {
                                                        "OutcomeClassDenomCount": [
                                                            {
                                                                "OutcomeClassDenomCountGroupId": "OG000",
                                                                "OutcomeClassDenomCountValue": "13"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "12"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Patients with metastatic disease",
                                        "OutcomeClassDenomList": {
                                            "OutcomeClassDenom": [
                                                {
                                                    "OutcomeClassDenomUnits": "Participants",
                                                    "OutcomeClassDenomCountList": {
                                                        "OutcomeClassDenomCount": [
                                                            {
                                                                "OutcomeClassDenomCountGroupId": "OG000",
                                                                "OutcomeClassDenomCountValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "0",
                "EventsTimeFrame": "Adverse events were collected at weekly time points after each vaccine administration for the duration of the study, an average of 7 months.",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine",
                            "EventGroupDescription": "Patients receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine",
                            "EventGroupDeathsNumAffected": "0",
                            "EventGroupDeathsNumAtRisk": "20",
                            "EventGroupSeriousNumAffected": "0",
                            "EventGroupSeriousNumAtRisk": "20",
                            "EventGroupOtherNumAffected": "20",
                            "EventGroupOtherNumAtRisk": "20"
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Erythema/swelling of vaccine sites",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "20",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain/soreness/tenderness of vaccine sites",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "20",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritus of vaccine sites",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "20",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Blister at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "16",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dry skin at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Ecchymosis at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Eczema at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Edema at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hives at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hyperpigmentation at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Warmth at vaccine site",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "14",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anorexia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Arthralgia",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Blisters",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chills",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Cramps",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dizziness",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Eczema",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Erythema",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fever",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Flu-like symptoms",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Headache",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Insomnia",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Lymphadenopathy",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Malaise",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Myalgia",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain, bone",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Sweats",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Urticaria",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventAssessmentType": "Non-systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Dr. Leisha Emens",
                    "PointOfContactOrganization": "Johns Hopkins University",
                    "PointOfContactEMail": "emensle@jhmi.edu"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M20355",
                            "ConditionBrowseLeafName": "Breast Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T861",
                            "ConditionBrowseLeafName": "Breast Cancer, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000003520",
                            "InterventionMeshTerm": "Cyclophosphamide"
                        },
                        {
                            "InterventionMeshId": "D000068878",
                            "InterventionMeshTerm": "Trastuzumab"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000007166",
                            "InterventionAncestorTerm": "Immunosuppressive Agents"
                        },
                        {
                            "InterventionAncestorId": "D000007155",
                            "InterventionAncestorTerm": "Immunologic Factors"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000018501",
                            "InterventionAncestorTerm": "Antirheumatic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018906",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
                        },
                        {
                            "InterventionAncestorId": "D000000477",
                            "InterventionAncestorTerm": "Alkylating Agents"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000019653",
                            "InterventionAncestorTerm": "Myeloablative Agonists"
                        },
                        {
                            "InterventionAncestorId": "D000074322",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M325",
                            "InterventionBrowseLeafName": "Trastuzumab",
                            "InterventionBrowseLeafAsFound": "Via",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M6417",
                            "InterventionBrowseLeafName": "Cyclophosphamide",
                            "InterventionBrowseLeafAsFound": "Time",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M9902",
                            "InterventionBrowseLeafName": "Immunosuppressive Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9891",
                            "InterventionBrowseLeafName": "Immunologic Factors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20294",
                            "InterventionBrowseLeafName": "Antirheumatic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20632",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3510",
                            "InterventionBrowseLeafName": "Alkylating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M1346",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ARhu",
                            "InterventionBrowseBranchName": "Antirheumatic Agents"
                        }
                    ]
                }
            }
        }
    }
}